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have been taken so far to assess the importance associated by the health care 
decision-makers to incorporate ethical principles into practice. The review 
serves as an initial basis for a survey to study US decision-makers’ perspectives 




MARKET ACCESS LESSONS FROM EXISTING PRODUCT DEVELOPMENT 
PARTNERSHIPS (PDPS)  
Ramadan F, Marinoni G, Ando G 
IHS, London, UK  
OBJECTIVES: To give an overview of recent PDPs between the pharmaceutical 
industry, the public sector, International Health Organizations (IHOs) and 
academia and draw best practices from two case studies, the Medicines for 
Malaria Venture (adaptive PDP) and the Malaria Vaccine Initiative (innovative 
PDP). METHODS: We surveyed the ‘Health Partnerships Database’ (HPD) to list 
PDPs to date. We searched for partnerships involving product development of 
drugs, vaccines and other pharmaceutical and diagnostics products. For the case 
studies, we analysed websites of the specific PDPs. RESULTS: The HPD lists 19 
PDPs, which can be classified into two categories: adaptive PDPs, i.e. research 
and development (R&D) initiatives focused on tailoring existing products to 
developing countries’ needs, and innovative PDPs, i.e. R&D initiatives focused on 
developing new products to address developing countries’ diseases. Existing 
PDPs focus on R&D of drugs (8 PDPs), vaccines (7 PDPs) and preventive and 
diagnostic techniques (4 PDPs) for diseases such as tuberculosis (TB, 5 PDPs), 
malaria (6 PDPs), meningitis (1 PDP) and HIV/AIDS (6 PDPs). Meanwhile, recently 
developed PDPs are tailored as an access-to-market strategy for essential and 
neglected disease treatments in developing countries (4 PDPs). In-depth analysis 
of two PDPs showed that 1) assessment of specific health care needs in 
developing countries prior to partnership initiation; 2) local government 
engagement in partnerships; 3) sustainability of funding flow accompanied by 
national expertise building; and 4) monitoring, reporting and transparent sharing 
of results are crucial for the success of PDPs. CONCLUSIONS: Multinational 
pharmaceutical companies are increasingly dedicating part of their development 
pipeline to developing-country diseases and turning to IHOs as strategic partners 
to secure market knowledge and access in these countries. However, most 
collaborations still happen around the “big three” diseases, Malaria, HIV/AIDS 
and TB.  
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OBJECTIVES: The goal of value-based insurance design (VBID) is to set encourage 
use of high-value therapies and discourage use of low-value ones by appealing to 
evidence of value, rather than a drug’s price, when tiering drugs and setting 
copayment levels. The aim of this study was to simulate the impact of an 
illustrative VBID approach on savings and health gains. METHODS: We used 
simulation to model an impact of a value-based formulary where drugs with less 
favorable cost-effectiveness (CE) had higher co-pays, and those with more 
favorable clinical effectiveness and CE were tiered with lower co-pays. Model 
inputs included drug utilization and cost data from the Medical Expenditure 
Panel Survey (MEPS) for 2008 and CE and health gain data from the published 
literature (Tufts CEA Registry). Estimates of behavioral effects of changing co-pay 
amounts on drug utilization were based on published literature. Modeled 
conditions included lipid disorders, hypertension, diabetes, esophageal 
disorders, and depression. In sensitivity analyses we ran the model using a large 
health plan’s 2010 drug cost and utilization data. RESULTS: In the esophageal 
and lipid-lowering scenarios, the total annual prescription costs decreased (3-
9%), in the hypertension scenario costs remained roughly the same, and in 
depression and diabetes costs increased slightly (2-4%). Total costs of care 
decreased in all but one scenario by 1-2%, and remained steady in the 
hypertension scenario. Health benefits also showed a positive impact across all 
scenarios, increasing total quality-adjusted life years gained by 118,000 to 
254,000, about 1%. The results were similar in scenarios using health plan data. 
CONCLUSIONS: The simulation illustrates the importance of evolving from the 
prevalent sub-optimal practice of tiering therapies based largely on drug costs to 
tiering based on overall value.  
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OBJECTIVES: The increase in premium-priced orphan drugs coupled with health 
care budget constraints will pressure managed care plans to consider restricting 
market access. Coverage and reimbursement of ten FDA-designated orphan 
drugs (alpha-glucosidase, bexarotene, bosentan, galsulfase, idursulfase, iloprost, 
laronidase, mecasermin, nitisinone, plerixafor) were analyzed for seven popular 
Medicare PDP (BCBS Rx, AARP Medicare Rx Preferred, Cigna Medicare Rx Plan 
One, Humana Enhanced, Aetna/CVS, EmblemHealth, UnitedHealthcare). 
METHODS: Formulary tier structure, monthly retail costs and utilization 
restrictions (UR)—pre-authorization (PA), quantity limits (QL) and step therapy 
(ST)—were obtained from CMS (www.medicare.gov). UR were assigned point 
values reflecting most to least restrictive—QL, 1; ST, 2; PA, 3; exclusion from 
formulary, 6. Each drug-plan combination can be assigned a maximum of 6 
points. Disease prevalences were obtained from a variety of sources. RESULTS: 
Monthly retail prices ranged from $782.45 (laronidase) to $11,845.25 
(mecasermin). Iloprost was most frequently excluded from formularies (2) and 
was subject to PA from the remaining five plans. The most frequently PA drug 
was mecasermin (6). There was slight negative correlation between price and 
prevalence of the disease for which the drugs were indicated (r2=0.080). There 
was a slight positive correlation between price and the number of UR points (r2= 
0.046). There was virtually no correlation between UR points and disease 
prevalence (r2=0.004). However, there is a moderate correlation between the 
number of plans that implement PA for a drug and that drug’s price (r2=0.322). 
CONCLUSIONS: With a wide range of drug prices, there is virtually no correlation 
between the number of UR points, drug price and disease prevalence. However, it 
is clear that PA is perceived to be the most effective cost-saving measure as it is 
used most for the more expensive drugs.  
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OBJECTIVES: The purpose of the study was to assess the relationship of 
pharmaceutical expenditures (PE) and other social and economic factors on life 
expectancy for different age groups in Organisation for Economic Co-operation 
and Development (OECD) countries. METHODS: This retrospective study 
analyzed data from the OECD database on the association between life 
expectancy in 2010 and PE, social/lifestyle (tobacco, alcohol, fruits, vegetables, 
and sugar consumption), and economic (health care expenditures and gross 
domestic product (GDP)) factors from a sample of 27 developed countries. Data 
were pooled according to gender at 40, 60, and 65 years while controlling for the 
lag variables of alcohol and tobacco (lagged 20 years), food intake variables (7 
years), and economic factors (12 years). All variables were transformed via 
logathrimic form to yield full elasticities. A bootstrapped random intercept 
regression model with sandwich estimators was conducted to determine which 
social and health factors were associated with a change in life expectancy. 
RESULTS: The mean life expectancy for males was 39.02±2.30 years for age 40, 
21.44±1.65 years for age 60, and 17.58±1.39 years for age 65. The mean life 
expectancy for females was 43.22±2.09 years for age 40, 25.21±1.68 years for age 
60, and 20.90±1.57 years for age 65. Results of the regression of life expectancy 
indicated significant associations (p≤0.05) of: male gender (coefficient=−0.146. CI: 
−0.157-0.135); age group of 60 years (−0.570, CI: −0.583-0.558); age group of 65 
years (−0.763, CI: −0.777-0.750); calorie intake (−0.144, CI: −0.246-0.041); fruit and 
vegetable intake (0.06, CI:0.036-0.084); overall health care expenditures (−0.047, 
CI: −0.092-0.001); and GDP (0.252, CI:0.189-0.314). Pharmaceutical expenditures 
were not associated with change in life expectancy for any age group. 
CONCLUSIONS: Across 27 OCED countries, specific food intake, GDP, and health 
care expenditures were significantly associated with altering life expectancy. 
Increased PE was not significantly associated with life expectancy.  
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OBJECTIVES: This study compares homeless patients’ utilization of the urban 
emergency department (ED) in the United States (US) with non-homeless 
patients and examines the relationship between homelessness and frequency of 
ED use, arrival to the ED by ambulance, waiting time to be seen, length and type 
of ED visit. METHODS: The emergency department component of the 2009 
National Hospital Ambulatory Care Survey database (NHAMCS-ED) was used for 
this cross-sectional, descriptive analysis. Patients were included if their patient 
residence was homeless or private residence and if they visited an urban ED. 
Descriptive statistics, bivariate analyses, and logistic regression were used to 
examine the relationship between demographics and ED use variables with 
homelessness. Nationally representative weights were applied to the estimates. 
RESULTS: The weighted sample size was 100,847,969 patient visits. A total of 
n=636,399 (0.63%) of the patients were homeless. The mean age of homeless 
patients was 44.0 years (95% CI: 41.7-46.3) compared to 34.7 years for non-
homeless patients (95% CI: 33.5-35.9, p<0.0001). The majority of homeless 
patients were male (75.9%) versus only 44.9% of non-homeless patients 
(p<0.0001). More homeless patients arrived to the ED via ambulance (45.2 vs. 
14.9%, p<0.0001). Homeless patients had a significantly different length of ED 
visit and number of ED visits in the past 12 months (both p=0.007) than non-
homeless patients. Homeless patients were more likely to be older (OR=1.02, 95% 
CI: 1.003-1.040), male gender (OR=3.34, 95% CI: 1.191-9.349), arrive to the ED via 
ambulance (OR=7.56, 95% CI: 4.045-14.137), have a longer length of ED visit 
(OR=1.002, 95%CI: 1.001-1.003), and have a past visit to the ED in the last 12 
months (OR=1.06, 95%CI: 1.033-1.080) than non-homeless patients. 
CONCLUSIONS: In 2009, homeless patients who visited US urban emergency 
departments were significantly different than non-homeless patients in their 
demographics, frequency, access, and pattern of ED use.  
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